Overview

For a distributor bringing a solid tumor 410-gene panel into a new territory, the commercial decision is inseparable from the regulatory one. A broad multi-gene panel occupies an awkward regulatory space: simultaneously a diagnostic device, a potential companion diagnostic, and a bioinformatics product. Each territory applies different rules to each layer, and misreading them delays launch or triggers recall. This guide maps the registration, quality and reimbursement considerations to resolve before signing.

IVD Registration and Companion Diagnostic Status

The first question is jurisdictional. In markets with a dedicated IVD pathway, the panel is typically registered as an in vitro diagnostic device, and the dossier must document the analytical validity of each claimed gene region. Where the panel includes genes paired to a specific therapy — such as KRAS for colorectal anti-EGFR agents or NTRK fusions for TRK inhibitors — regulators may classify those claims as companion diagnostics, raising the evidentiary bar. Request the supplier's registration status per country and confirm whether companion-diagnostic claims are bundled into existing clearance.

Regulators increasingly demand that clinical reporting be restricted to variants with established actionability, and that the bioinformatics pipeline be locked and version-controlled. Ask for the supplier's variant-classification policy and evidence of ACMG-style harmonization, since a panel marketed on gene count alone will not survive review.

Laboratory Quality and Bioinformatics Validation

Because most large panels run as laboratory-developed tests in central labs, the regulatory center often shifts to the lab itself. Confirm the testing laboratory holds relevant accreditation — typically ISO 15189 and, where applicable, CAP — and that the platform is listed on the registration. The lab must also show proficiency through external quality-assessment schemes; request recent EQA results for the gene regions.

Bioinformatics is the quiet risk. A 410-gene panel depends on alignment, variant calling and copy-number algorithms, and small parameter changes can alter a result. Demand that the pipeline is validated against reference materials, that limits of detection are defined per variant type, and that a versioned software release accompanies every update.

Market Access: Coding, Reimbursement and Launch Strategy

Investigate the coverage pathway before launch: does the territory reimburse comprehensive genomic profiling under an oncology NGS code, or must each indication be justified separately? Companion-diagnostic status often unlocks reimbursement faster, because the test is tied to a covered therapy. Prepare a health-economic dossier documenting turnaround time and tissue versus sequential single-gene testing.

Finally, align regulatory and commercial planning. Registration for a broad panel routinely exceeds that for a single biomarker, so build launch milestones around the expected clearance date. Engage the notified body early and submit a pre-submission meeting where the pathway is ambiguous.

FAQ

Q: Is a 410-gene panel registered as a companion diagnostic or a general IVD? A: It depends on territory and claims. Genes paired to a specific therapy, like KRAS or NTRK, may trigger companion-diagnostic classification with a higher evidence bar, while the rest registers as general IVD.

Q: What laboratory standards should a distributor verify? A: Confirm ISO 15189 and, where applicable, CAP accreditation, recent EQA results for the panel's gene regions, and a validated bioinformatics pipeline with defined limits of detection.

Q: How does companion-diagnostic status affect market access? A: It can speed reimbursement because the test is tied to a covered therapy, but it raises the evidentiary burden in registration, so plan launch milestones around the clearance date.